Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events

Aug 04, 2022 7:30am EDT

XOMA Declares Quarterly Preferred Stock Dividends

Jun 20, 2022 7:30am EDT

XOMA to Present at H.C. Wainwright Global Investment Conference

May 17, 2022 4:05pm EDT

XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

May 05, 2022 7:30am EDT

XOMA Declares Quarterly Preferred Stock Dividends

Mar 21, 2022 7:30am EDT

XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Mar 10, 2022 7:30am EST

XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

Mar 08, 2022 7:30am EST

XOMA to Present at the 42nd Annual Cowen Health Care Conference

Mar 01, 2022 7:30am EST

XOMA to Present at Aegis Capital Corp Investor Conference

Feb 17, 2022 7:30am EST

XOMA Declares Quarterly Preferred Stock Dividends

Dec 23, 2021 7:30am EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...43
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2023 XOMA Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2023 XOMA • Powered by GeneratePress
    Scroll back to top